Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.
about
The role of NKT cells in tumor immunityRoles and relevance of mast cells in infection and vaccinationThe Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8(+) T Cell GenerationActivation of B cells by non-canonical helper signalsNKT cell networks in the regulation of tumor immunityRole of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune responseThe regulatory role of invariant NKT cells in tumor immunityThe immunoregulatory role of type I and type II NKT cells in cancer and other diseasesA glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primatesUsing magnetic resonance imaging to evaluate dendritic cell-based vaccinationInvariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid AInvariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humansExploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccinesRobust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine.Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge.Recognition of lyso-phospholipids by human natural killer T lymphocytes.Vaccine-induced myeloid cell population dampens protective immunity to SIVAltered CD8(+) T cell immunodominance after vaccinia virus infection and the naive repertoire in inbred and F(1) mice.Baculovirus capsid display potentiates OVA cytotoxic and innate immune responses.Activation of iNKT cells by a distinct constituent of the endogenous glucosylceramide fraction.Tissue-Specific Distribution of iNKT Cells Impacts Their Cytokine Response.Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity.Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice.Bystander activation of iNKT cells occurs during conventional T-cell alloresponsesA Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse ModelFrom mice to humans - murine intelligence for human CD8+ T cell vaccine design.Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells.Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against LeishmaniaThe requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvantsCombination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.Glycolipids as immunostimulating agents.TLR gateways to CD1 function.Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumorsExpression of CD1c enhances human invariant NKT cell activation by α-GalCer.Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response.Carbohydrates and T cells: a sweet twosome.
P2860
Q24648939-5B5E991E-7020-4CC7-BB5A-A2675A2E10DBQ26777264-61F5A8F7-2599-4979-A6A2-347D4D83326DQ26797344-807743DE-493F-4BC8-9301-6A8E7BA492ABQ26866169-78706EFC-AEEA-4C60-B292-A51A3D55A5BBQ26866223-CB866428-8ED4-48DF-9248-D57EB3A32BFAQ26996330-BFE703BC-8521-4F4F-9E55-57E12FDAB683Q27023425-90C7E479-5A2C-4330-9B77-C5DFAD9D7F81Q27027556-1DA13A2A-D07B-418A-A9C9-B93C396F81C7Q27303293-371D7F94-5205-4529-8CD8-E8BDD6F4FAB5Q27316977-A9832579-A9EA-4050-94AD-79C592E2413EQ28294740-0ADDF2DC-AF6A-4783-A1E7-3ABDAC23B3D4Q28511526-7D08929C-497C-4C47-A028-11C410867D34Q28741462-971CE3F8-E52A-48E6-A3D1-30186CA898FDQ30405708-A7F2C99F-E8E5-4F46-B6B2-95D378FACDDCQ31153121-EDFB41B9-968E-498C-9D7A-6F18C9C10A63Q33512901-8F8DF558-59CD-45FB-9B1B-71EB8816290DQ33685961-D19252FD-6BA0-4588-B532-1FDD870D0528Q33754153-3A4786ED-4493-4A0A-B36D-DD8F089D0991Q34019812-1070FE88-DB87-417C-B7AD-097B7576080DQ34218428-D2F84CF2-025D-4EDA-887D-9F833B0A1E00Q34493722-3CBE6566-C877-4779-91B5-64AB9910B4ADQ34519826-EFA24281-85FB-4526-BABF-B307E85DB205Q34983932-107AA1DA-8B0E-4EBB-9A1D-8B993B4339C5Q35890019-1673FAB5-3308-43BF-A20B-78F29489109FQ35931493-3A5EF3BB-596C-42CA-9B11-3DF5A722AA28Q36065972-A4E35F6B-0A43-48D6-9F17-FCE8426C5EC7Q36229067-62F94EB9-7059-419F-BA8A-798D0422C5AAQ36251325-6443ABB9-D79F-4AED-8589-A8CC96B6994AQ36398927-4DE5CDCD-4492-4346-BBFC-4A8C17522859Q36439026-1AA04C2D-A250-44D5-8E59-5311A8A1FEEAQ36471827-D88A340E-E223-4E16-8DED-1EC8E50DC67EQ36474450-102D333E-6828-426E-BB2E-BC6CA69383F2Q36503451-6A51F55A-9127-442C-BB53-F6AD2EE6A13AQ36517889-371019AF-209A-4888-972A-F55156FAD588Q36541616-8034328A-AAFD-4627-8591-FD5972320CDFQ36542800-460FDADC-319D-40D8-A4FB-2C2378CFA8DBQ37002097-4382655F-E97A-4FB7-A61B-ABE1A981679FQ37040200-94B3BF86-E4CD-4F4A-A01F-285AD806F477Q37108806-EDA94FE7-0460-41FC-8D74-1B6FF58164BEQ37118132-24DBEE71-00A7-421D-A094-D7BD388FF690
P2860
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Utilizing the adjuvant propert ...... T cell-mediated immunotherapy.
@en
type
label
Utilizing the adjuvant propert ...... T cell-mediated immunotherapy.
@en
prefLabel
Utilizing the adjuvant propert ...... T cell-mediated immunotherapy.
@en
P2093
P2860
P50
P356
P1476
Utilizing the adjuvant propert ...... T cell-mediated immunotherapy.
@en
P2093
Bini Mathew
Kaye J Williams
Richard R Schmidt
Sarah Jane Lunt
Tsung Wen Chong
P2860
P304
P356
10.1172/JCI200422046
P407
P50
P577
2004-12-01T00:00:00Z